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Abstract: Despite the strong progress has been made in the field of melanoma epigenetics, the importance of 
genome-wide demethylation or hypomethylation remains underestimated. However, this phenomenon might also 
reflect important epigenetic alterations due to its ability to cause genetic instability. Furthermore, no methylation-
based distinction has been drawn among the diverse primary melanoma subtypes. To assess global methylation we 
measured the methylation level on the 6 CpG sites of LINE1 sequences in 46 primary melanomas in association 
with patients’ survivals and the clinicopathological characteristics of specimens. We demonstrate that LINE1 hypo-
methylation is accompanied by the shortened relapse-free survival of melanoma patients; however, Cox regression 
analysis shows a direct relationship between the overall loss of 5-methylcytosine and metastatic potential of primary 
melanomas, which is confirmed by Kruskal-Wallis tests with Dunn’s Multiple Comparison Post-test showing that not 
only the presence but the number of metastases during the 5-year follow-up period is associated with the transpo-
son demethylation. In this study, we demonstrate the strong influence of global DNA demethylation in the metastatic 
formation of primary melanomas during the follow-up period.
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Introduction
Global DNA hypomethylation is an important 
component of epigenetic modifications causing 
genetic instability [1-3]. The global hypomethyl-
ation is related to the overall loss of 5-methyl-
cytosine which is believed to correspond to the 
methylcytosine of repetitive transposable ele-
ments (LINE and SINE sequences) having inte-
grated into the human genome during evolution 
and gained protection from transcription due to 
their higher levels of methylcytosine [4, 5]. As 
these elements are reactivated by hypomethyl-
ation, they can recombine with each other, 
causing karyotypic instability [3]. The LINE1 
sequences are 5000 to 6000 bp long, and 104 
copies of these elements are spread through-
out the genome [2, 6]. Considering that LINE1 
elements along with Alu (SINE) sequences con-
stitute 40% of the human genome, it is clear 
why the literature generalises the transposable 
demethylation as global hypomethylation [2].
In melanoma, the most aggressive form of skin 
neoplasms, the presence of genome-wide 
hypomethylation has been reported by several 
groups [7-9]. The degree of global demethyl-
ation has been proven sufficient in distinguish-
ing a benign naevus from primary and meta-
static melanomas [7]; however, no demethy- 
lation-based distinction has been drawn among 
the diverse primary melanoma subtypes with 
different clinical behaviours. Nonetheless, the 
relationship between transposable hypomethyl-
ation and patients’ survival is still a topic of 
doubt and discussion, as a single group has 
reported the prolonged survival of stage III mel-
anoma patients with hypomethylation [5]. 
However, this finding stands in sharp contrast 
to data from other types of cancers, which 
exhibit global demethylation [10, 11].
Our aim was to investigate the extent of LINE1 
methylation level in primary malignant melano-
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ma samples and to determine that how trans-
posable methylation is associated with mela-
noma progression.
Materials and methods
Melanoma samples; genomic DNA extraction
Forty-six primary melanomas were used for 
LINE1 methylation analysis; the clinicopatho-
logical data of the melanoma patients are sum-
marised in Table 1.
The tumour tissues were obtained from the 
Department of Dermatology, University of 
Debrecen, Hungary. All human studies were 
conducted in accordance with the principles 
outlined in the Declaration of Helsinki, were 
approved by the Regional and Institutional 
Ethics Committee of the University of Debrecen 
Medical and Health Science Centre and were 
conducted according to regulations (Protocol 
#2836-2008). Written informed consent was 
obtained from each patient. 
After surgical excision, the G-spin™ Genomic 
DNA Extraction Kit (Intron, Korea) was used to 
isolate high-molecular-weight DNA from 46 pri-
mary melanomas according to the manufactur-
er’s protocol. To determine the quantity of DNA 
obtained, we used a NanoDrop ND-1000 UV-Vis 
Spectrophotometer. The DNA integrity was veri-
fied via 1.2% agarose gel electrophoresis.
Bisulphite pyrosequencing of LINE1
Global hypomethylation was measured via 6 
CpG sites located on the transposable LINE1 
sequence. The genomic DNA specimens (n=46) 
were treated by applying sodium bisulphite 
using the EZ DNA Methylation-Gold Kit (Zymo 
Research, Orange, CA, USA) to 500 ng of each 
DNA sample following the manufacturer’s rec-
ommendations. LINE1 pyrosequencing analysis 
was performed on the PSQ96 (Biotage) using 
the following primers: sense, 5’-BIOTIN-
TAGGGAGTGTTAGATAGTGG, antisense, 5’-AACT- 
CCCTAACCCCTTAC, and sequencing primer, 
5’-AACTCCCTAACCCCTTAC. Hot-start PCR was 
performed using the HotStarTaq Master Mix Kit 
(Qiagen), and the pyrosequencing was carried 
out in accordance with the manufacturer’s pro-
tocol (Biotage). The target CpGs were evaluated 
by converting the resulting pyrograms to numer-
ical values for peak heights. The following 




To estimate the effect of the LINE1 methylation 
status on patients’ survival, the LINE1 methyla-
tion level represented by continuous variables 
was dichotomised at its cut-off value deter-
mined for each CpG site by the ROC curve anal-
ysis in which the true positive rate (Sensitivity) 
is plotted in function of the false positive rate 
Table 1. Clinical-pathological parameters of pri-
mary melanomas




    SSM1 30
    NM2 16
Gender
    Female 24
    Male 22
Age (years)
    20-50 14
    ≥50 32
Breslow thickness (mm)3
    ≤2 18
    2-4 12
    >4 16
Clark’s stage
    I-III (early) 27
    IV-V (late) 19
Location of primary tumor
    Extremity 25
    Trunk 20
    Head 1
Metastasis formation4
    Absent 24
    Present 22
Patient’s survival5
    Alive 24
    Exitus 22
Ulceration
    Absent 24
    Present 22
1superficial spreading melanoma; 2nodular melanoma; 3thick-
ness categories are based on the current staging system; 
4metastasis of the examined primary tumours; 5patients with at 
least 5-year follow-up period were included.
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Figure 1. Relationship be-
tween survival and LINE1 
hypomethylation in primary 
melanomas. A: Kaplan-
Meier analysis of primary 
melanoma (n=46) patients 
survival according to LINE1 
methylation levels which 
were measured by pyrose-
quencing at 6 CpG sites. 
Kaplan- Meyer function for 
Overall Survival rate (OS) 
was calculated for CM pa-
tients according to cut-off 
values (determined by ROC 
curves) of methylation of 
CpG_1, CpG_2, CpG_3, 
CpG_4, CpG_5 and CpG_6 
sites of LINE1, respectively. 
Dashed red line refers for 
patients with LINE1 meth-
ylation above, whereas 
solid green line depicts 
LINE1 methylation below 
the cut-off value, respec-
tively. Cumulative survival 
by LINE1 methylation level 
was evaluated using the 
Log-Rank test and reported 
P values are two sided. B: 
Clinical cofounders includ-
ing age and gender of pa-
tients, Breslow thickness, 
Clark level, histological sub-
type, metastasis formation 
during the 5-year follow up 
period and tumour surface 
ulceration was examined by 
Cox proportional hazards 
regression model whereas 
the effect of hypomethyl-
ation on survival was pre-
sented as Hazard Ratios 
(HR) with corresponding 
95% Confidence Intervals 
(CI).
(100-Specificity) for different cut-off points of a 
parameter. Each point on the ROC curve repre-
sents a sensitivity/specificity pair correspond-
ing to a particular decision threshold. The area 
under the ROC curve (AUC) is a measure of how 
well a parameter can distinguish between the 
hypomethylated and non-hypomethylated 
groups. Kaplan-Meier survival probability curve 
was drawn for the groups using the log-rank 
test to examine the difference in survival by 
LINE1 methylation level. The clinical parame-
ters including patient age and gender, Breslow 
thickness, Clark level, histological subtype, 
metastasis formation during the 5-year follow 
up period and tumour surface ulceration were 
examined by the Cox proportional hazards 
regression model, and the effect of hypometh-
ylation on the survival was presented as hazard 
ratios (HR) with corresponding 95% confidence 
intervals (CI). To control for the above-noted 
additional confounders, a stepwise regression 
was applied to select variables.
As the initial D’Agostino and Pearson omnibus 
normality test revealed that LINE1 methylation 
values do not follow the Gaussian distribution, 
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we used the nonparametric Mann Whitney and 
Kruskal-Wallis tests with Dunn’s Multiple 
Comparison Post-test to verify the direct rela-
tionship between the LINE1 methylation status 
and clinical parameters.
Results
Relationship of patients’ survival and LINE1 
hypomethylation
Our experimental design included 46 primary 
malignant melanoma samples (Table 1). Six 
CpG sites on the LINE1 transposable sequence 
were measured for their global methylation pat-
tern. Not having demonstrated a Gaussian dis-
tribution, the continuous variables of the LINE1 
pyrosequencing results were dichotomised, 
and the simplicity groups were constructed 
using the threshold values determined by the 
ROC curve analysis. The threshold levels were 
the following: CpG_1 (55.5), CpG_2 (68.1), 
CpG_3 (46.8), CpG_4 (56.8), CpG_5 (83.6) and 
CpG_6 (61.6).
The sample groups were defined as LINE1 
hypomethylated (specimens with a LINE1 meth-
ylation < threshold value) and non-hypomethyl-
ated (samples with a LINE1 methylation ≥ 
threshold value).
As shown in Figure 1A, the Kaplan-Meier curve 
analysis revealed significant differences 
between the hypomethylated and non-hypo-
methylated patients, with a decreased overall 
survival (OS) rate for the hypomethylated group 
for each CpG site (CpG_1: p=0.011; CpG_2: 
p=0.018; CpG_3: p=0.03; CpG_4: p=0.012; 
CpG_5: p=0.006; and CpG_6: p=0.006). 
Notably, the hazard ratios (HR) were higher 
than 3.0 in each hypomethylated group for all 
six CpG sites. The Cox proportional hazard 
regression model allowed for the control of 
additional clinical covariates as well as for the 
patient gender and age. As the stepwise regres-
sion method indicated metastatic potential 
(when primary melanomas develop metastasis 
during the five-year follow up period) to influ-
ence patient survival, this potential was includ-
ed in the model, and the adjusted HR values 
were calculated. As demonstrated in Figure 1B, 
the adjusted HR values did not remain higher 
than 1.46 nor did the adjusted p-values remain 
significant. 
LINE1 hypomethylation is related to metastatic 
capacity of melanomas
As the stepwise method of Cox proportional 
hazard regression model suggested the direct 
Figure 2. Association be-
tween the number of meta- 
stasis and LINE1 hypome- 
thylation. A: Primary melano-
mas that developed metas-
tasis were divided into sub- 
groups according to the 
number of metastasis form- 
ed during the follow-up pe-
riod and Kruskall Wallis test 
with Dunn’s Multiple Com-
parison Post-test was applied 
to study association of global 
hypomethylation and meta-
static capacity which reach- 
ed significant level in the 
majority of CpGs. B: Logistic 
regression model for LINE1 
hypomethylation and the clin-
ical cofounders summarize 
the association of metastat-
ic capacity and global dem- 
ethylation in primary mela-
nomas. For each CpGs high 
Odds Ratios (OR) were evalu-
ated in the hypomethylated 
sample groups with corre-
sponding 95% Confidence In-
tervals (CI). Association rea- 
ched significance for CpG_1. 
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relationship of the overall loss of 5-methylcyto-
sine with metastatic potential, we built a logis-
tic regression model with a stepwise selection 
for LINE1 hypomethylation and for the clinical 
parameters. Figure 2 demonstrates the asso-
ciation of metastatic capacity and global 
demethylation in primary melanomas. For each 
CpG site, we found high odds ratios (OR) for the 
hypomethylated sample groups; however, the 
OR remained significant for CpG1 (Figure 2B). 
The Mann-Whitney test confirmed that global 
hypomethylation of all six CpGs was significant-
ly associated with metastasis formation. To 
increase the statistical power of the univariate 
test, primary melanomas with metastasis were 
divided into subgroups according to the num-
ber of metastases developed during the follow-
up period, and the Kruskal-Wallis test with 
Dunn’s Multiple Comparison Post-test was 
applied to measure the strength of the relation-
ship. Figure 2A depicts significantly different 
levels of global methylation for most CpGs, 
except for CpG4, among tumours without 
metastasis and melanomas with more than 
one metastasis over 5 years. 
Discussion
The so-called ‘genome-wide hypomethylation’ 
is believed to correspond to the loss of methyl-
cytosine, which belong to repetitive transpos-
able elements and can cause karyotypic insta-
bility [3, 12], as the genome contains 
approximately 5000 full-length LINE1 ele-
ments, 60-100 of which are still capable of ret-
rotransposition [4, 13]. It was indicated that 
LINE1 hypomethylation can offer a new facility 
that emphasises early detection in the case of 
applying a technical approach that may make 
rapid, systematic screening possible [14].
To date, genome-wide hypomethylation has 
been demonstrated in 16 melanoma cell lines 
compared to melanocytes via repetitive ele-
ments [7]. Regrettably, we were unable to 
determine the actual clinical effects of genome-
wide methylation, as the above-mentioned 
study focused only on comparing cell lines to 
controls instead of drawing a demethylation-
based distinction between cell lines with differ-
ent characteristics.
Notably, data from other types of neoplasms, 
such as ovarian and colon cancer [6], have 
established a relationship between shortened 
survival and global demethylation [15]. 
Additionally, Hoshimoto et al. described the 
shortened relapse-free survival of demethyl-
ated melanomas [9]. Sigalotti et al. conducted 
a valuable study aimed at estimating the LINE1 
methylation status of 42 short-term cultures 
from surgically removed IIIC melanomas. 
Surprisingly, among the three LINE1 CpG sites, 
the hypomethylation of two CpG sites was 
associated with prolonged patient survival [5].
Our study comprised 46 primary melanomas 
measured at 6 LINE1 CpG sites using quantita-
tive pyrosequencing. In contrast to Sigalotti’s 
research group, we demonstrated a shortened 
relapse-free survival in LINE1 hypomethylation 
patients in all six CpG sites using the log-rank 
test. More importantly, using the same statisti-
cal approach as Sigalotti’s group, the metastat-
ic capacity was significantly associated with 
global hypomethylation for any of the 6 CpGs. 
When the primary melanomas with metastasis 
were divided into subgroups based on the num-
ber of metastases formed during the 5-year 
follow-up period, significantly different levels of 
global methylation were observed between the 
groups for the majority of CpGs. Our results 
contrast with the findings of Sigalotti’s group 
[5]. However, their study comprised cell cul-
tures derived from homogeneous staged speci-
mens, whereas our experiments were per-
formed using primary melanomas characteristic 
of distinct clinical behaviour.
In conclusion, we demonstrated that LINE1 
hypomethylation status strongly predicts the 
metastatic capacity of primary melanomas 
suggesting the role of transposons’ hypometh-
ylation in the progression of primary mela- 
nomas. 
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